MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody

Targeting cancer antigens by T cell-engaging bispecific antibody (BiAb) or chimeric antigen receptor T cell therapy has achieved successes in hematological cancers, but attempts to use it to fight solid cancers have been disappointing, in part due to antigen escape. MEK inhibitor had limited activit...

Full description

Bibliographic Details
Main Authors: Hongjian Li, Cheng Huang, Zongliang Zhang, Yunyu Feng, Zeng Wang, Xin Tang, Kunhong Zhong, Yating Hu, Gang Guo, Liangxue Zhou, Wenhao Guo, Jianguo Xu, Hui Yang, Aiping Tong
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Oncology
Subjects:
trametinib
B7-H3
immunotherapy
bispecific antibody
non-small-cell lung cancer
bladder cancer
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01527/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01527/full

Similar Items